However, the lack of effect in PL45 could be explained not only by its mutations in KRAS, TP53 or DPC4, which are commonly found in PC, but also by its mutation in BRCA2 gene, which could confer chemoresistance in PC as recently described by Wang et al. [68]. Here, TP53 is linked to pachyonychia congenita.